News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Apr 24, 2024, 09:58

KEYNOTE-A18 summarised by Sergio Cifuentes

Sergio Cifuentes, Cancer Research Project Manager at 

”KEYNOTE-A18.

  • Pembrolizumab + CRT in LACC
  •  mPFS NR in pembrolizumab group

24m PFS: 68% vs 57%

  • Pembrolizumab + CRT led to a 30% reduction in DR
  • OS at 24m: 87% vs 81%

Grade 3 or higher AE: 75% vs 69%.”

Read further.
Source: Sergio Cifuentes/X

cancer CENEIT México cervical cancer clinical trials CRT KEYNOTE-A18 trial OncoDaily Oncology pembrolizumab Sergio Cifuentes
Special Coverage
Science
Feb 22, 2025, 16:16
Angela Lamarca: Current management of advanced HCC
Blog
Feb 22, 2025, 16:04
Eric Lehrer: Role of WBRT in multifocal LGG
Science
Feb 22, 2025, 16:00
Malak Alharbi: Diagnostic and therapeutic challenges in PRCA secondary to SMM
Blog
Feb 22, 2025, 15:54
Patrick Forde: Great day for lung cancer care
Science
Feb 22, 2025, 15:48
Shankar Siva: Whats new in stage IV cancer?
Science
Feb 22, 2025, 15:33
Updated ESMO Clinical Practice Guideline on Hepatocellular Carcinoma
Science
Feb 22, 2025, 15:14
Erman Akkus: Stage specific characterization of early-onset colorectal cancer
Blog
Feb 22, 2025, 15:04
John Gordon: Successful CAR Tcell Therapy - "It's a Bug's Life"
Blog
Feb 22, 2025, 14:43
Giannis Mountzios: How active ADCs against oncogene-addicted NSCLC?
Science
Feb 22, 2025, 14:10
Yan Leyfman: Advancing CAR T-Cell Therapy - Off-the-Shelf Allogeneic Approach
Science
Feb 22, 2025, 13:28
Elvina Almuradova: Immunotherapy for HPV-Associated Cancers
Opinion
Feb 22, 2025, 13:10
Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding